Ignite Creation Date:
2024-05-06 @ 2:56 PM
Last Modification Date:
2024-10-26 @ 1:40 PM
Study NCT ID:
NCT04470544
Status:
RECRUITING
Last Update Posted:
2021-01-11
First Post:
2020-07-09
Brief Title:
Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19
Sponsor:
Alan Bryce
Organization:
Academic and Community Cancer Research United
Study Overview
Official Title:
RECOVER Phase 2 Randomized Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE a TMPRSS2 Inhibitor
Status:
RECRUITING
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RECOVER
Brief Summary:
To determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care SOC treatment will increase the proportion of patients alive and free from respiratory failure at Day 28 in SARS-CoV-2 as compared to SOC treatment with placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None